Endothelial Progenitor Cells

NCT01686269 | Unknown DMC

• 1 other identifier: FEMH-95-C-018
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Vascular stenosis as a result of neointimal hyperplasia is a major clinical problem that has an impact on multiple and diverse disciplines, including cardiology (coronary restenosis), cardiothoracic and vascular surgery (saphenous vein and polytetrafluoroethylene \[PTFE\] graft failure), neurology (carotid stenosis), nephrology (dialysis access dysfunction), and transplant medicine (chronic allograft rejection in hearts and kidneys). \[1\] In marked contrast to the deleterious effects of smooth muscle progenitor cells on neointimal hyperplasia, circulating endothelial progenitor cells (EPCs) are believed to play an important role in vascular repair and in the inhibition of neointimal hyperplasia. \[2\] Endothelial progenitor cells (EPCs) circulate in adult peripheral blood and contribute to neovascularization. Satoshi et al. have demonstrated that lineage-committed EPCs and CD34-positive mononuclear cells, their putative precursors, are mobilized during an acute ischemic event in humans. \[3\] Reduced levels of circulating EPCs independently predict atherosclerotic disease progression, thus supporting an important role for endogenous vascular repair to modulate the clinical course of coronary artery disease. \[4\] These observations prompt the hypothesis that circulating EPCs may provide an endogenous repair mechanism to counteract surgery-induced endothelial cell injury and to replace dysfunctional endothelium perioperatively. Therefore, the investigators examined whether levels of circulating EPCs correlate with time course and outcomes of coronary artery bypass surgery to establish a clinical role of endogenous endothelial repair mediated by circulating EPCs.

Conditions

Coronary Artery Disease

Keywords

Endothelial progenitor cell; coronary artery bypass

Interventions

blood collecting PROCEDURE

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• age from 18 to 85 years
• signed written informed consent
• angiographically documented coronary artery disease and indicated for coronary artery bypass surgery

You may not qualify if:

• clinical or biochemical evidence for the presence of concomitant inflammatory disease
• chronic renal insufficiency (serum creatinine \> 1.4 mmol/L)
• impaired left ventricular ejection fraction (\< 45%)
• autoimmune or malignant disease
• thrombocytopenia (\< 100 000/L)
• anemia (hemoglobin \< 8.5 g/dL)
• inability to understand the consent form
• previous coronary bypass surgery
• severe peripheral arterial occlusive disease or atrial fibrillation

Sponsors & Collaborators

• Far Eastern Memorial Hospital: lead

Study Sites (1)

Far Eastern Memorial Hospital

Taipei, 220, Taiwan

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Officials

• Kuan-Ming Chiu, MD

  Far Eastern Memorial Hospital

  STUDY DIRECTOR

Central Study Contacts

Kuan-MIng Chiu, MD

CONTACT

886-2-89667000; kmchius@yahoo.com.tw

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 6, 2009
• First Posted: September 18, 2012
• Study Start: March 1, 2007
• Last Updated: September 18, 2012

Record last verified: 2007-01

Locations

TW (1)